Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 May 13

PMID 35557845

Authors

Sumaiya Ahmed

Gregory L Hundemer

Affiliations

Soon will be listed here.

Abstract

Primary aldosteronism is the most common and modifiable form of secondary hypertension. Left untreated, primary aldosteronism leads high rates of cardiovascular, metabolic, and kidney disease. Therefore, early diagnosis and targeted therapy are crucial to improve long-term patient outcomes. In the case of unilateral primary aldosteronism, surgical adrenalectomy is the guideline-recommended treatment of choice as compared to alternative medical therapies such as mineralocorticoid receptor antagonist medications. Surgical adrenalectomy is not only highly successful in reversing the biochemical abnormalities inherent to primary aldosteronism, but also in mitigating the long-term risks associated with this disease. Indeed, as opposed to medical treatment alone, surgical adrenalectomy offers the potential for disease cure. Within this review article, we review the existing evidence highlighting the benefits of surgical over medical treatment for unilateral primary aldosteronism.

Citing Articles

Impact of confirmatory test results on subtype classification and biochemical outcome following unilateral adrenalectomy in patients with primary aldosteronism.

Daneshpour H, Brudgam D, Stufchen I, Heinrich D, Bidlingmaier M, Beuschlein F Front Endocrinol (Lausanne). 2024; 15:1495959.

PMID: 39678193 PMC: 11637841. DOI: 10.3389/fendo.2024.1495959.

Predicting the resolution of hypertension following adrenalectomy in primary aldosteronism: Controversies and unresolved issues a narrative review.

Marzano L Langenbecks Arch Surg. 2024; 409(1):295.

PMID: 39354235 DOI: 10.1007/s00423-024-03486-7.

Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.

Mao M, Feng R, Khan N, Tao L, Tang P, Zhao Y BMC Surg. 2024; 24(1):242.

PMID: 39182043 PMC: 11344387. DOI: 10.1186/s12893-024-02530-z.

References

Duncan 3rd J, Fuhrman G, Bolton J, Bowen J, Richardson W . Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg. 2001; 66(10):932-5; discussion 935-6. View

Sellgren F, Koman A, Nordenstrom E, Hellman P, Hennings J, Muth A . Outcomes After Surgery for Unilateral Dominant Primary Aldosteronism in Sweden. World J Surg. 2019; 44(2):561-569. DOI: 10.1007/s00268-019-05265-8. View

Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y . Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension. 2018; 72(4):874-880. PMC: 6207209. DOI: 10.1161/HYPERTENSIONAHA.118.11086. View

Nanba K, Omata K, Gomez-Sanchez C, Stratakis C, Demidowich A, Suzuki M . Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension. 2019; 73(4):885-892. PMC: 6416065. DOI: 10.1161/HYPERTENSIONAHA.118.12070. View

Savard S, Amar L, Plouin P, Steichen O . Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013; 62(2):331-6. DOI: 10.1161/HYPERTENSIONAHA.113.01060. View

Wu V, Wang S, Chang C, Hu Y, Lin L, Lin Y . Long term outcome of Aldosteronism after target treatments. Sci Rep. 2016; 6:32103. PMC: 5009379. DOI: 10.1038/srep32103. View

Peng K, Liao H, Chan C, Lin W, Yang S, Tsai Y . Presence of Subclinical Hypercortisolism in Clinical Aldosterone-Producing Adenomas Predicts Lower Clinical Success. Hypertension. 2020; 76(5):1537-1544. DOI: 10.1161/HYPERTENSIONAHA.120.15328. View

Rossi G, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B . Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension. 2018; 71(4):585-591. DOI: 10.1161/HYPERTENSIONAHA.117.10596. View

Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A . Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013; 98(12):4826-33. DOI: 10.1210/jc.2013-2805. View

10.

Celen O, OBrien M, MELBY J, Beazley R . Factors influencing outcome of surgery for primary aldosteronism. Arch Surg. 1996; 131(6):646-50. DOI: 10.1001/archsurg.1996.01430180072015. View

11.

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

12.

Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F . Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017; 69(14):1811-1820. DOI: 10.1016/j.jacc.2017.01.052. View

13.

Takamatsu K, Takeda T, Hattori S, Tanaka N, Morita S, Matsumoto K . Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma. Clin Endocrinol (Oxf). 2020; 92(6):503-508. DOI: 10.1111/cen.14176. View

14.

Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T . Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest. 1995; 18(5):370-3. DOI: 10.1007/BF03347840. View

15.

Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A . Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol. 2018; 3(8):768-774. PMC: 6143072. DOI: 10.1001/jamacardio.2018.2003. View

16.

Barrett Mueller K, Bender S, Hong K, Yang Y, Aronovitz M, Jaisser F . Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension. 2015; 66(5):988-97. PMC: 4600033. DOI: 10.1161/HYPERTENSIONAHA.115.06172. View

17.

Vorselaars W, Nell S, Postma E, Zarnegar R, Drake F, Duh Q . Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism. JAMA Surg. 2019; 154(4):e185842. PMC: 6484800. DOI: 10.1001/jamasurg.2018.5842. View

18.

Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H . Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab. 2017; 103(1):16-24. DOI: 10.1210/jc.2017-01442. View

19.

Kobayashi H, Abe M, Nakamura Y, Takahashi K, Fujita M, Takeda Y . Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. Hypertension. 2019; 74(3):630-638. DOI: 10.1161/HYPERTENSIONAHA.119.13131. View

20.

Ribstein J, Cailar G, Fesler P, Mimran A . Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005; 16(5):1320-5. DOI: 10.1681/ASN.2004100878. View